Phibro holder may sell 350K shares, $12.4M

PHIBRO ANIMAL HEALTH CORP (PAHC) received a Form 144 notice indicating that BFI Co. LLC, identified as a 10% stockholder, may sell up to 350,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC under Rule 144.

Rhea-AI Filing Summary

PHIBRO ANIMAL HEALTH CORP (PAHC) received a Form 144 notice indicating that BFI Co. LLC, identified as a 10% stockholder, may sell up to 350,000 shares of Class A Common Stock through Goldman Sachs & Co. LLC under Rule 144. The proposed sale, with an aggregate market value of $12,355,000, references approximately 21,105,569 shares outstanding and contemplates sales beginning on September 16, 2026. The shares were originally acquired on April 14, 2014 in a private placement and exchange of securities, and the notice states that the sales are made in connection with a selling plan dated May 20, 2026 that is intended to comply with Rule 10b5-1(c).

Key Figures

Shares to be sold: 350,000 shares Aggregate market value of shares to be sold: $12,355,000 Shares outstanding: 21,105,569 shares +3 more

6 metrics

Shares to be sold 350,000 shares Class A Common Stock covered by the Form 144 notice

Aggregate market value of shares to be sold $12,355,000 Reported for the 350,000 Class A shares

Shares outstanding 21,105,569 shares Referenced outstanding Class A Common Stock in the Form 144

Approximate date of sale September 16, 2026 Planned start for potential Rule 144 sales

Acquisition date of shares April 14, 2014 Date shares were obtained via private placement and exchange

Selling plan date May 20, 2026 Date of selling plan intended to comply with Rule 10b5-1(c)

Key Terms

Rule 144, Rule 10b5-1(c), private placement, selling plan

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"selling plan dated 5/20/2026 that is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

private placement financial

"Private placement from issuer | Phibro Animal Health Corporation"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

selling plan financial

"sales of shares set forth herein are made in connection with a selling plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing report for PAHC?

It reports that BFI Co. LLC, a 10% stockholder of Phibro Animal Health Corporation, has filed notice of a potential sale of 350,000 shares of Class A Common Stock under Rule 144 through Goldman Sachs & Co. LLC.

How many PAHC shares are planned to be sold and what is their value?

The notice covers up to 350,000 shares of PAHC Class A Common Stock, with an indicated aggregate market value of $12,355,000. The filing also references approximately 21,105,569 shares outstanding for the class.

Who is selling the PAHC shares and through which broker?

The securities are to be sold for the account of BFI Co. LLC, a 10% stockholder, with Goldman Sachs & Co. LLC listed in connection with the Class A Common Stock. The notice is signed “Goldman Sachs & Co. LLC on behalf of Daniel Bendheim.”

When may the PAHC share sales begin under this Form 144?

The filing lists an approximate date of sale of September 16, 2026 for the potential sale of 350,000 PAHC Class A shares pursuant to Rule 144.

How and when were the PAHC shares originally acquired?

The Class A Common Stock covered by this notice was acquired on April 14, 2014 in a private placement from the issuer and via an exchange of securities with Phibro Animal Health Corporation.

Is the PAHC Form 144 sale linked to a Rule 10b5-1 plan?

Yes. The remarks state that the sales of shares are made in connection with a selling plan dated May 20, 2026 that is intended to comply with Rule 10b5-1(c).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 05:18 PM Accepted by SEC EDGAR 09/16/2026 - 05:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001601607
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Phibro Animal Health Corporation
SEC File Number	001-36410
Address of Issuer	Glenpointe Centre East, 3rd Floor 300 Frank W. Burr Boulevard, Suite 21 Teaneck NEW JERSEY 07666
Phone	1-201-329-7300
Name of Person for Whose Account the Securities are To Be Sold	BFI Co. LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	350000	12355000	21105569	09/16/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	04/14/2014	Private placement from issuer	Phibro Animal Health Corporation			350000	04/14/2014	Exchange of Securities

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 5/20/2026 that is intended to comply with Rule 10b5-1(c).
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Daniel Bendheim
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)